NO20061416L - Pyrimidotiofenforbindelser - Google Patents
PyrimidotiofenforbindelserInfo
- Publication number
- NO20061416L NO20061416L NO20061416A NO20061416A NO20061416L NO 20061416 L NO20061416 L NO 20061416L NO 20061416 A NO20061416 A NO 20061416A NO 20061416 A NO20061416 A NO 20061416A NO 20061416 L NO20061416 L NO 20061416L
- Authority
- NO
- Norway
- Prior art keywords
- optionally substituted
- nra
- hydrogen
- alk2
- alk1
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 abstract 2
- 101710113864 Heat shock protein 90 Proteins 0.000 abstract 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- -1 carboxyl ester Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Abstract
Forbindelser med formel (I) er inhibitorer for HSP90-aktivitet in vitro eller in vivo, og har anvendelse ved behandlingen av blant annet kreft: hvor R2 er en gruppe med formel -(Ar1)m-(Alk1)p-(Z)r-(Alk2)g-Q, hvor Ar1 er et eventuelt substituert aryl- eller heteroarylradikal, Alk1 og Alk2 er eventuelt substituerte toverdige C1-C3-alkylen- eller C2-C3-alkenylenradikaler, m, p, r og s er uavhengig av hverandre 0 eller 1, Z er -0-, -S-, -(C=0)-, -(C=S)-, -SO2-, -C(=0)0-, -C(=O)NRA-, -C(=S)NRA-, -SO2NRA-, -NRAC(=O)-, -NRA-S02- eller -NRA-, hvor RA er hydrogen eller C1-C6-alkyl, og Q er hydrogen eller et eventuelt substituert karbosyklisk eller heterosyklisk radikal; R3 er hydrogen, en eventuell substituent eller et eventuelt substituert (C1-C6)alkyl-, aryl- eller heteroarylradikal ; og R4 er en karboksylester-, karboksamid- eller sulfonamidgruppe.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0320300A GB0320300D0 (en) | 2003-08-29 | 2003-08-29 | Pyrimidothiophene compounds |
GB0327924A GB0327924D0 (en) | 2003-12-02 | 2003-12-02 | Pyrimidothiophene compounds |
GB0414467A GB0414467D0 (en) | 2004-06-29 | 2004-06-29 | Pyrimidothiophene compounds |
PCT/GB2004/003641 WO2005021552A1 (en) | 2003-08-29 | 2004-08-26 | Pyrimidothiophene compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061416L true NO20061416L (no) | 2006-05-23 |
Family
ID=34279360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061416A NO20061416L (no) | 2003-08-29 | 2006-03-28 | Pyrimidotiofenforbindelser |
Country Status (13)
Country | Link |
---|---|
US (2) | US7820658B2 (no) |
EP (1) | EP1675861B1 (no) |
JP (1) | JP4783731B2 (no) |
KR (1) | KR101139314B1 (no) |
AU (1) | AU2004268820B2 (no) |
BR (1) | BRPI0413861A (no) |
CA (1) | CA2537135C (no) |
EA (1) | EA009920B1 (no) |
ES (1) | ES2559779T3 (no) |
HK (1) | HK1095591A1 (no) |
NO (1) | NO20061416L (no) |
NZ (1) | NZ546044A (no) |
WO (1) | WO2005021552A1 (no) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0416168D0 (en) * | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
GB0420719D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1836161B1 (en) * | 2004-12-22 | 2016-07-20 | BHI Limited Partnership | Methods and compositions for treating amyloid-related diseases |
BRPI0609509A2 (pt) * | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
DE102005022977A1 (de) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
RU2441010C2 (ru) * | 2005-12-21 | 2012-01-27 | Эбботт Лэборетриз | Противовирусные соединения |
AU2007207536A1 (en) * | 2006-01-17 | 2007-07-26 | Signal Pharmaceuticals, Llc | Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith |
WO2007104944A1 (en) * | 2006-03-11 | 2007-09-20 | Vernalis (R & D) Ltd. | Pyrrolopyrimidine derivatives used as hsp90 inhibitors |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
US20070259820A1 (en) * | 2006-05-03 | 2007-11-08 | The Regents Of The University Of Michigan | Methods and reagents for activating heat shock protein 70 |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
SI3851447T1 (sl) | 2006-10-12 | 2024-02-29 | Bellus Health Inc. | Postopki, spojine, sestavki in vehikli za dostavljanje 3-amino-1- propansulfonske kisline |
FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
WO2008059368A2 (en) * | 2006-11-17 | 2008-05-22 | Pfizer Products Inc. | Fused 2-amino pyrimidine compounds and their use for the treatment of cancer |
CA2675677A1 (en) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors |
RU2009136343A (ru) | 2007-03-01 | 2011-04-10 | Чугаи Сейяку Кабусики Кайся (Jp) | Макроциклическое соединение |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
CA2697399C (en) | 2007-09-14 | 2016-01-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
CA2698929C (en) | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
RS51660B (en) | 2007-09-14 | 2011-10-31 | Ortho-Mcneil-Janssen Pharmaceuticals Inc. | 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE |
GB0718433D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
JP5433582B2 (ja) | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
WO2010025890A1 (en) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
EP2430022B1 (en) | 2009-05-12 | 2013-11-20 | Janssen Pharmaceuticals, Inc. | 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2430031B1 (en) | 2009-05-12 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
JP2013502424A (ja) | 2009-08-17 | 2013-01-24 | メモリアル スローン−ケタリング キャンサー センター | 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法 |
FR2949467B1 (fr) * | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
WO2012062750A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
AU2011328203B2 (en) | 2010-11-08 | 2015-03-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
ES2766623T3 (es) | 2011-07-08 | 2020-06-12 | Sloan Kettering Inst Cancer Res | Usos de inhibidores etiquetados HSP90 |
MX2014000648A (es) | 2011-07-19 | 2014-09-25 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y sus usos. |
BR112014029301A2 (pt) | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
GB201217704D0 (en) * | 2012-10-03 | 2012-11-14 | Ucb Pharma Sa | Therapeutic agents |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
US20150031697A1 (en) * | 2013-07-26 | 2015-01-29 | Wisconsin Alumni Research Foundation | Method for preventing ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
KR20220038826A (ko) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
WO2015136557A2 (en) * | 2014-03-11 | 2015-09-17 | Godavari Biorefineries Limited | Cancer stem cell targeting compounds |
EP3116882A4 (en) * | 2014-03-11 | 2017-08-02 | Godavari Biorefineries Ltd. | Compounds for eradicating or inhibiting proliferation of cancer stem cells |
CN107074806B (zh) | 2014-05-13 | 2021-04-23 | 纪念斯隆-凯特琳癌症中心 | Hsp70调节子以及其制造和使用方法 |
AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
ES2954453T3 (es) | 2014-06-13 | 2023-11-22 | Yuma Therapeutics Inc | Compuestos de pirimidina y métodos que utilizan los mismos |
CN118059093A (zh) * | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
CN110891568A (zh) | 2017-04-07 | 2020-03-17 | 凯斯西储大学 | 用于治疗冠状动脉病症的短链脱氢酶活性的抑制剂 |
ES2965494T3 (es) * | 2018-04-12 | 2024-04-15 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}benzamida y los correspondientes derivados de piridina-carboxamida como plaguicidas |
CN115124550B (zh) * | 2020-10-26 | 2024-04-02 | 山东大学 | 一种特异性热休克蛋白90α亚型抑制剂制备及其应用 |
WO2022089449A1 (zh) * | 2020-10-26 | 2022-05-05 | 山东大学 | 一种特异性热休克蛋白90α亚型抑制剂制备及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0438261A3 (en) | 1990-01-16 | 1992-02-26 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic glutamic acid derivatives, their production and use |
JPH0578362A (ja) * | 1990-01-16 | 1993-03-30 | Takeda Chem Ind Ltd | 縮合複素環化合物,その製造法,用途及び中間体 |
EP2336133A1 (en) * | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
-
2004
- 2004-08-26 EA EA200600509A patent/EA009920B1/ru not_active IP Right Cessation
- 2004-08-26 EP EP04768197.8A patent/EP1675861B1/en not_active Expired - Lifetime
- 2004-08-26 AU AU2004268820A patent/AU2004268820B2/en not_active Ceased
- 2004-08-26 BR BRPI0413861-9A patent/BRPI0413861A/pt active Search and Examination
- 2004-08-26 NZ NZ546044A patent/NZ546044A/en not_active IP Right Cessation
- 2004-08-26 KR KR1020067004012A patent/KR101139314B1/ko active IP Right Grant
- 2004-08-26 JP JP2006524418A patent/JP4783731B2/ja not_active Expired - Fee Related
- 2004-08-26 CA CA2537135A patent/CA2537135C/en not_active Expired - Fee Related
- 2004-08-26 US US10/569,287 patent/US7820658B2/en not_active Expired - Fee Related
- 2004-08-26 WO PCT/GB2004/003641 patent/WO2005021552A1/en active Application Filing
- 2004-08-26 ES ES04768197.8T patent/ES2559779T3/es not_active Expired - Lifetime
-
2006
- 2006-03-28 NO NO20061416A patent/NO20061416L/no not_active Application Discontinuation
-
2007
- 2007-03-08 HK HK07102556.5A patent/HK1095591A1/xx not_active IP Right Cessation
-
2010
- 2010-01-21 US US12/690,983 patent/US8642594B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1675861A1 (en) | 2006-07-05 |
JP4783731B2 (ja) | 2011-09-28 |
US20070043044A1 (en) | 2007-02-22 |
AU2004268820A1 (en) | 2005-03-10 |
WO2005021552A1 (en) | 2005-03-10 |
JP2007533611A (ja) | 2007-11-22 |
NZ546044A (en) | 2009-09-25 |
CA2537135A1 (en) | 2005-03-10 |
KR20070055414A (ko) | 2007-05-30 |
US8642594B2 (en) | 2014-02-04 |
KR101139314B1 (ko) | 2012-04-26 |
CA2537135C (en) | 2013-10-08 |
HK1095591A1 (en) | 2007-05-11 |
AU2004268820B2 (en) | 2011-07-21 |
US7820658B2 (en) | 2010-10-26 |
EP1675861B1 (en) | 2015-12-23 |
BRPI0413861A (pt) | 2006-10-24 |
US20100120767A1 (en) | 2010-05-13 |
EA009920B1 (ru) | 2008-04-28 |
ES2559779T3 (es) | 2016-02-15 |
EA200600509A1 (ru) | 2006-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061416L (no) | Pyrimidotiofenforbindelser | |
NO20054195L (no) | Isoksazolforbindelser som inhibitorer for varmesjokkproteiner | |
DE60304059D1 (de) | 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs | |
ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
NO20070343L (no) | N-(1 -(1 -benzyl-4-fenyl-1 H-imidazol-2-yl)-2,2-dimetylpropyl)benzamid derivater og relaterte forbindelser som kinesin spindelprotein (KSP) inhibitorer for behandling av kreft | |
ATE454152T1 (de) | 2-aminopyrimidin-derivate als raf-kinase-hemmer | |
ATE540021T1 (de) | Hydroxansäurederivate als inhibitoren der enzymatischen hdac-aktivität | |
HUP0301113A2 (hu) | Pirrolidinszármazékok, mint ciklusos amp-specifikus foszfodiészteráz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TW200730501A (en) | Heterocyclic derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase I | |
ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
HUP0302955A2 (hu) | HMG-CoA reduktáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk koleszterinnel kapcsolatos betegségek kezelésére | |
NO20060670L (no) | N3-substituerte imidazopyridin C-kit inhibitorer | |
NO20072605L (no) | Nytt antranilinsyrederivat eller et salt derav | |
NO20024154D0 (no) | Pyrimidinforbindelser | |
GEP20074148B (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
CY1111083T1 (el) | Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38 | |
HRP20070430T3 (en) | (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity | |
NO20073791L (no) | Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer | |
DE602005022764D1 (de) | Piperidin- und azetidinderivate als glyt1-inhibitoren | |
EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
EA200701780A1 (ru) | Противоопухолевое средство | |
MXPA06003250A (es) | Oximas de benzofurano substituidas. | |
MY143245A (en) | 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases | |
EA200501730A1 (ru) | Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина | |
NO20082226L (no) | 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: CANCER RESEARCH TECHNOLOGY LTD, GB |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |